medigraphic.com
ISSN 1025-0255 (Electronic)

2016, Number 1

<< Back

AMC 2016; 20 (1)

Streptokinase almost 30 years after its demonstrated efficacy in acute myocardial infarction

Casola CR, Casola CE, Castillo SG, Casola BE

Language: Spanish
References: 34
Page: 96-107
PDF size: 882.06 Kb.


ABSTRACT

Background: from the study of the Italian Group per lo Studio del la Strepto-chinasi nell’Infarto Miocardico, in 1986 the approach of the treatment of acute myocardial infarction changed; however, there is currently controversy about the choice of treatment.
Objective: to compare the advantages and disadvantages of the different thrombolytic in the treatment of acute myocardial infarction and their use versus percutaneous coronary intervention.
Methods: a review of 310 articles published in PubMed, Hinari and Medline was made using the reference management software Endnote. Thirty-four citations were selected to make the review, 17 of them from the last five years.
Development: there are two reperfusion strategies in the treatment of acute myocardial infarction: the pharmacologic and the interventional. Among the fibrinolytic (drugs) are those with lytic action, as streptokinase and urokinase, and other group with localized lysis as anistreplase, alteplase, tenecteplase and reteplase. The first ones, with respect to the second group, have the disadvantage of the risk of bleeding and the antigenic activity of streptokinase, not presented by the rest of fibrinolytic drugs. In the first two hours there is no significant difference regarding the mortality reduction with both strategies; after this time, it improves with the intervention.
Conclusions: percutaneous coronary intervention is the ideal form of reperfusion in patients with acute myocardial infarction but, at the same time, it is not yet a common practice in developed countries. Reperfusion with thrombolytic remains the first alternative in second-level hospitals and streptokinase is a safe treatment option. Thus, it is demonstrated that the GISSI study is updated.


REFERENCES

  1. Sandoya E. Ensayos clínicos que cambiaron la práctica de la cardiología: fortalezas y debilidades. Rev Urug Cardiol [Internet]. Jun 2007 [citado 15 May 2013];22(1):[aprox. 5 p.]. Disponible en: http://www.scielo.edu.uy/scielo.php?pid=S1688-04202007000100006&script=sci_arttext

  2. Grupo Italiano per lo Studio de la Strepto-chinasinell’InfartoMiocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986 Feb 22;1(8478):397-402.

  3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988 Aug 13;2(8607):349-60.

  4. Weitz JI. Hemostasia, trombosis, fibrinólisis y enfermedad cardiovascular. En: Bonow OR, Mann DL, Libby P, editores. Branwuald tratado de cardio-logía. 9na ed. Barcelona: Elsevier; 2013. p. 1188-1891.

  5. Bertomeu V, Cequier A, Bernal JL, Alfonso F, An-guita MP, Muñiz J, et al. Mortalidad intrahospitala-ria por infarto agudo de miocardio. Relevancia del tipo de hospital y la atención dispensada. Estudio RECALCAR. Rev Esp Cardiol [Internet]. Dic 2013 [citado 15 May 2013];66(12):[aprox. 7 p.]. Dispo-nible en: http://www.revespcardiol.org/es/mortalidad-intrahospitalaria-por-infarto-agudo/articulo/90255801/.

  6. Zaman MJ, Stirling S, Shepstone L, Ryding A, Flather M, Bachmann M, et al. The association be-tween older age and receipt of care and outcomes in patients with acute coronary síndromes: a co-hort of the Myocardial Ischaemia National Audit Project (MINAP). Eur Heart J. 2014;35:1551–8.

  7. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in sus-pected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994 Feb;5(8893):311-22.

  8. González Ferreiro R, Raposeiras Roubín S, Abu Assi E, Castiñeiras Busto M, García Acuña JM, González Juanatey JR. Tratamiento no invasivo del infarto agudo de miocardio. Perfil clínico de los pacientes y variables predictoras de mal pronóstico. Rev Esp Cardiol [Internet]. Abr 2015 [citado 2 Jun 2015];68(4):[aprox. 5 p.]. Disponible en: http://www.revespcardiol.org/es/tratamiento-no-invasivo-del-infarto/articulo/90398536/.

  9. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008 Aug 16;372(9638):570-84.

  10. Kline EM, Smith DD, Martin JS. In-hospital treat-ment delays in patients treated with thrombolytic therapy: a report of the GUSTO yime to treatment substudy. Circulation. 1990;86(Suppl 1):702.

  11. LATE Study Group. Late assessment of thrombo-lytic efficacy (LATE) Study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993 Sep 25;342(8874):759-66.

  12. EMERAS Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 1993 Sep 25;342(8874):767-72.

  13. Atzema CL, Austin PC, Tu JV, Schull MJ. Emergen-cy department triage of acute myocardial infarction patients and the effect on outcomes. Ann Emerg Med. 2009 Jun;53(6): 736-45.

  14. Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarc-tion. N Engl J Med. 2006 Nov 30;355(22):2308-20.

  15. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006 Nov 7;114(19):2019-25.

  16. Washington AE, Lipstein SH. The Patient-Centered Outcomes Research Institute—promoting better information, decisions, and health. N Engl J Med. 2011;365: e31.

  17. Steg G, James SK, Atar D, Badano LP, Bloms-tromLundqvist C, Borger MA, et al. Guía de prácti-ca clínica de la ESC para el manejo del infarto agu-do de miocardio en pacientes con elevación del segmento ST. Rev Esp Cardiol [Internet]. Ene 2013 [citado 20 Ene 2014];66(1):[aprox. 5 p.] Disponi-ble en: http://www.revespcardiol.org/es/guia-practica-clinica-esc-el/articulo/90180910/.

  18. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996 Sep 21;348(9030):771-5.

  19. NHS Foundation Trust. Harefield Hospital After your primary angioplasty [Internet]. London: Royal Brompton Hospital; 2012 [cited 2014 Ene 20]. Available from: http://www.rbht.nhs.uk/pati ents/condition/primary-angioplasty/.

  20. Gierlotka M, Gasior M, Wilczek K, Hawranek M, Szkodzinski J, Paczek P, et al. Reperfusion by pri-mary percutaneous coronary intervention in pa-tients with ST-segment elevation myocardial in-farction within 12 to 24 hours of the onset of symptoms (from a prospective national observa-tional study [PL-ACS]). Am J Cardiol. 2011 Feb 15;107(4):501-8.

  21. Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al. Mechanical reperfu-sion in patients with acute myocardial infarction presenting more than 12 hours from symptom on-set: a randomized controlled trial. JAMA. 2005 Jun 15;293(23): 2865-72.

  22. Ndrepepa G, Kastrati A, Mehilli J, Antoniucci D, Schomig A. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarc-tion presenting 12 to 48 hours from onset of symptoms. JAMA. 2009 Feb 4;301(5):487-8.

  23. Hochman JS, Lamas GA, Buller CE, Dzavik V, Rey-nolds HR, Abramsky SJ, et al. Coronary interven-tion for persistent occlusion after myocardial in-farction. N Engl J Med. 2006 Dec 7;355(23):2395-407.

  24. Menon V, Pearte CA, Buller CE, Steg PG, Forman SA, White HD, et al. Lack of benefit from percuta-neous intervention of persistently occluded infarct arteries after the acute phase of myocardial in-farction is time independent: insights from Oc-cluded Artery Trial. Eur Heart J [Internet]. 2009 Jan [citado 2014 Jan 20];30(2):[about 6 p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639108/.

  25. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or Pri-mary PCI in ST-Segment Elevation Myocardial In-farction. N Engl J Med. 2013;368:1379-87.

  26. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. ACCF/AHA Guide-line for the Management of ST-Elevation Myocar-dial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29;127(4): 529-55.

  27. Elliott M, Antman, Morrow DA. Infarto de mio-cardio con elevación del segmento ST: tratamien-to. En: Bonow OR, Mann DL, Libby P, editores. Branwuald tratado de cardiología. 9na ed. Barce-lona: Elsevier; 2013. p. 1132-41.

  28. Kawasaki T, Akakabe Y, Yamano M, Miki S, Kami-tani T, Kuribayashi T, et al. Vagal enhancement as evidence of residual ischemia after inferior myo-cardial infarction. Pacing Clin Electrophysiol. 2009 Jan;32(1):52-8.

  29. Gersh BJ, Stone GW, White HD, Holmes DR. Phar-macological facilitation of primary percutaneous coronary intervention for acute myocardial infarc-tion: Is the slope of the curve the shape of the future? JAMA. 2005 Feb 23;293(8):979-86.

  30. Goldstein P, Lapostolle F, Steg G, Danchin N, As-sez N, Montalescot G, et al. Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: Key prehospital and emergency room treatment strategies. Eur J Emerg Med. 2009 Oct;16(5):244-55.

  31. Kang SH, Suh JW, Yoon CH, Cho MC, Kim YJ, Chae SC, et al. Sex Differences in Management and Mortality of Patients With ST-Elevation Myo-cardial Infarction (from the Korean Acute Myocar-dial Infarction National Registry). Am J Cardiol. 2012 Mar 15;109(6):787-93.

  32. Zhang Z, Fang J, Gillespie C, Wang G, Hong Y, Yoon PW. Age-Specific Gender Differences in In-Hospital Mortality by Type of Acute Myocardial In-farction. Am J Cardiol. 2012 Apr 15;109(8):1097-103.

  33. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, StenestrandU, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syn-drome: data from the SWEDEHEART register. J Intern Med. 2010 Jul;268(1):40-9.

  34. Ames S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14;122(11):1056-67.




2020     |     www.medigraphic.com